← All indications
Proteinuria
The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
Subtype terms (2)
More specific conditions that are subtypes of Proteinuria in the MeSH hierarchy.
- Albuminuria
50 drugs (38 approved, 12 experimental)
- Hemoglobinuria
5 drugs approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (39)
- metformin
- abacavir
- corticotropin
- maraviroc
- ambrisentan
- candesartan
- tenofovir
- amlodipine
- ritonavir
- rosuvastatin
- lamivudine
- atazanavir
- valsartan
- sparsentan
- lopinavir
- shenyankangfu
- aliskiren
- fosamprenavir
- emtricitabine
- darunavir
- trandolapril
- triamterene
- calcitriol
- bortezomib
- verapamil
- vildagliptin
- furosemide
- ramipril
- eplerenone
- benazepril
- +9 more
Phase 3 trials (15)
Phase 2 trials (15)
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (45)
- Abbott
- Merck
- Novartis
- Mallinckrodt
- Sponsor GmbH
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Huazhong University of Science and Technology
- Ajou University
- Baylor University
- Changhua Christian Hospital
- Cornell University
- Georgetown University
- Hospital General Universitario Gregorio Marañon
- Hospital Italiano de Buenos Aires
- Hospital Britanico
- Medical University of Gdansk
- Seoul National University
- The Rogosin Institute
- Yonsei University
- Chinese University of Hong Kong
- Fudan University
- Laval University
- Southeast Renal Research Institute
- Tsinghua University
- University of Vienna
- University of Minnesota
- Jiao Tong University
- University of Strasbourg
- Rush University
- +15 more
Organization Involved with Phase 3 Indications (22)
- Daiichi Sankyo
- Sankyo
- AstraZeneca
- Genentech
- Bayer
- National Institutes of Health (NIH)
- Gottfried Wilhelm Leibniz Universität Hannover
- Instituto Nacional de Cardiologia Ignacio Chavez
- Melbourne Health
- National Cheng Kung University
- Osaka University
- University of Melbourne
- University of Miami
- University of Tehran
- Mayo Clinic
- University of Calgary
- University of Ljubljana
- Government of Korea
- Mario Negri Institute
- Technical University of Dresden
- University of Western Ontario
- Yeshiva University
Organization Involved with Phase 2 Indications (19)
- Encysive
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- National Center for Complementary and Integrative Health (NCCIH)
- National Heart, Lung, and Blood Institute (NHLBI)
- Harvard University
- Nanjing Medical University
- University of Edinburgh
- University of Groningen
- Sun Yat-Sen University
- University of Texas at Houston
- South Texas Health Care System, San Antonio, TX
- University of Alabama, Birmingham
- University of Texas, San Antonio
- Department of Veteran Affairs
- National Kidney Foundation
- Chinese Academy of Medical Sciences
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (9)
Organization Involved with Other Experimental Indications (20)
- Los Angeles Biomedical Research Institute
- Metropolis Medical
- Nanjing University
- Shaheed Faghihi Hospital
- University of Southern Denmark
- West Virginia University
- University of Virginia
- Istanbul University
- Nazareth Hospital
- Shanghai Municipal Health Bureau
- University of Naples Frederico II
- The Nazareth Hospital, Israel
- Southern Medical University
- Nazareth EMMS Hospital
- Western Galilee Hospital
- The Danish Council for Strategic Research
- Lundbeck
- Shantou University
- University of Antwerp
- Jinlin University